阿仑单抗相关性弥漫性肺泡损伤-1 例报告。
Alemtuzumab-associated diffuse alveolar damage - a case report.
机构信息
Neurology and Clinical Neurophysiology, University Hospital of Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany.
Internal Medicine I-Cardiology, University Hospital of Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany.
出版信息
BMC Neurol. 2020 Sep 23;20(1):357. doi: 10.1186/s12883-020-01934-7.
BACKGROUND
Identifying causes of alemtuzumab induced respiratory symptoms in Multiple Sclerosis (MS) patients is crucial.
CASE PRESENTATION
We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of alemtuzumab treatment. A 42-year-old female developed progressive non-productive cough and exertional dyspnea 2 months after alemtuzumab treatment. DAD was diagnosed histopathologically by lung biopsy. The patient recovered completely, alemtuzumab was not continued.
CONCLUSIONS
Our case highlights another pathomechanism for non-infective lung-disorders in alemtuzumab treated MS patients. DAD is a potential, albeit rare side effect of alemtuzumab, broadening the spectrum of non-infective lung disorders that should be considered in the diagnostic work-up.
背景
确定多发性硬化症 (MS) 患者接受阿仑单抗治疗后出现呼吸症状的原因至关重要。
病例介绍
我们报告了一例 MS 患者在接受阿仑单抗治疗第一疗程后发生弥漫性肺泡损伤 (DAD) 的病例。一名 42 岁女性在接受阿仑单抗治疗后 2 个月出现进行性无痰干咳和劳力性呼吸困难。通过肺活检组织病理学诊断为 DAD。患者完全康复，未继续使用阿仑单抗。
结论
我们的病例强调了阿仑单抗治疗的 MS 患者发生非感染性肺部疾病的另一种发病机制。DAD 是阿仑单抗的潜在但罕见的副作用，扩大了应在诊断性检查中考虑的非感染性肺部疾病谱。
Zotero 插件